Business Context and Reporting Period
Company: VisionSys AI Inc (formerly TCTM Kids IT Education Inc.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Transformation: The Company has completed a strategic pivot, divesting its professional education business (Divestiture 2024) and its STEM education business (Disposition 2025). It is now exclusively focused on developing and commercializing Brain-Computer Interface (BCI) technologies and related AI-enabled healthcare solutions. The STEM education business is presented as discontinued operations for all periods.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 (RMB '000) | 2025 (US$ '000) | 2024 (RMB '000) |
|---|---|---|---|
| Net Revenues (Continuing Ops) | 1,039 | 149 | 0 |
| Net Income (Loss) from Continuing Ops | (40,033) | (5,725) | (13,851) |
| Net Income (Loss) from Discontinued Ops | 1,758,903 | 251,521 | (573,251) |
| Total Net Income (Loss) | 1,718,870 | 245,796 | (587,102) |
| Cash and Cash Equivalents (End of Period) | 53,445 | 7,643 | 1,504 |
| Intangible Assets (Net) | 51,430 | 7,354 | 0 |
Note: The 2025 Net Income is primarily driven by a one-time gain on the disposal of discontinued operations. Continuing operations remain unprofitable.
Material Changes vs. Prior Period
- Revenue Shift: Continuing operations revenue increased from nil in 2024 to RMB 1.0 million in 2025, generated by the new BCI subsidiary (Beijing Wangwen). This represents the initial commercialization of technical services.
- Discontinued Operations Gain: A significant gain of RMB 1.69 billion (US$ 241 million) was recognized in 2025 due to the disposal of the STEM education business. This gain resulted primarily from the derecognition of net liabilities associated with the divested entities.
- Operating Expenses: General and administrative expenses for continuing operations increased 179% to RMB 40.2 million, driven by personnel costs and amortization of newly acquired intangible assets (BCI software).
- Impairment: The Company recognized an impairment loss of RMB 21.0 million on its BCI intangible assets due to R&D delays and revenue shortfalls.
- Liquidity: Cash and cash equivalents from continuing operations grew significantly to RMB 53.4 million, bolstered by financing activities including the issuance of Class A ordinary shares.
Guidance, Outlook, and Risks
Outlook: Management intends to focus on non-invasive BCI products (wellness, sleep support, rehabilitation) in the near term, with potential expansion into medical applications in the medium to long term. The Company expects to generate revenue from technical service contracts and device sales.
Material Risks:
- Commercialization Uncertainty: The BCI business is in an early stage with limited operating history. There is no assurance that the Company will achieve profitability or that market acceptance will materialize.
- Regulatory Environment: Operations are subject to complex PRC regulations regarding medical devices, data security, and AI. Failure to obtain necessary approvals could halt commercialization.
- PCAOB Inspection Risk: As a foreign private issuer with operations in China, the Company faces potential delisting risks under the Holding Foreign Companies Accountable Act (HFCA) if the PCAOB cannot inspect its auditors.
- Subsequent Financing: A private placement announced in March 2026 allows for settlement in cryptocurrencies, introducing volatility risk to the actual proceeds received.
Investor Verification Checklist
- Discontinued Operations Gain: Verify the sustainability of the RMB 1.69 billion gain; it is a one-time event from divesting liabilities, not recurring operating income.
- Continuing Operations Viability: Assess the RMB 40 million operating loss from continuing operations against the RMB 1 million revenue to evaluate the burn rate of the new BCI strategy.
- Intangible Asset Valuation: Review the impairment testing assumptions for the RMB 76 million BCI software asset, given the RMB 21 million impairment already recognized.
- Cryptocurrency Settlement: Monitor the March 2026 private placement to determine if proceeds are settled in fiat or volatile cryptocurrencies.
- Regulatory Approvals: Confirm the status of medical device registrations required for the Company's planned BCI products in China.